Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 9th, 2026

The BioPharm Brief: Trials Expand Cancer, Eye Disease and Obesity Care

New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.

October 9th, 2026

FAQ: How Much Do You Know About ASOs?

Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.

October 9th, 2026

How Surrogate Endpoints Are Shortening Multiple Myeloma Drug Timelines

Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.

Phase 2b data show petrelintide reduced body weight and glycemic control markers versus placebo as Zealand and Roche move the amylin analog into phase 3a testing. Credit: Stock.Adobe.com/littlewolf1989

October 9th, 2026

Petrelintide Meets Primary Endpoint in Obesity and Type 2 Diabetes

Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.

Red squirrel eyes, macro photo. Conjunctivitis, eye disease. | Image credit: © Kryuchka Yaroslav - © Kryuchka Yaroslav - stock.adobe.com

October 9th, 2026

Innovent's Sycume Meets Phase 3 Goal in Inactive Thyroid Eye Disease

Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.

The FDA approved atezolizumab with chemotherapy for stage III dMMR colon cancer, citing phase 3 ATOMIC data. Credit: Stock.Adobe.com/Sebastian Kaulitzki.

October 9th, 2026

FDA Approves Tecentriq Plus Chemotherapy for Stage III Mismatch Repair-Deficient Colon Cancer

Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.

October 8th, 2026

The BioPharm Brief: Rare Disease Trials, mRNA Innovation, and Funding

New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.

fda on paper texture | Image credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com

October 8th, 2026

Ultragenyx to Sell Rare Pediatric Disease Voucher for $210 Million

Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.